Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD | Market Cap | 290.60M +194.3% |
| Revenue (ttm) | n/a |
| Net Income | -39.78M |
| EPS | -2.53 |
| Shares Out | 20.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,832 |
| Open | 13.12 |
| Previous Close | 13.69 |
| Day's Range | 13.12 - 14.00 |
| 52-Week Range | 6.36 - 18.98 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 17.67 (+26.67%) |
| Earnings Date | Aug 12, 2026 |
About Satellos Bioscience
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research ... [Read more]
Analyst Summary
According to 3 analysts, the average rating for MSCL stock is "Strong Buy." The 12-month stock price target is $17.67, which is an increase of 26.67% from the latest price.
News
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Satellos Bioscience NASDAQ: MSLE said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne musc...
Satellos Bioscience Inc TRAILHEAD Study Data Update Call Transcript
Satellos Bioscience Inc TRAILHEAD Study Data Update Call Transcript
Satellos Bioscience Transcript: Study update
Six-month interim data from the TRAILHEAD study in adults with DMD showed improvements in muscle fat fraction, upper limb effort, and quality of life, with a favorable safety profile and no serious adverse events. These results support further development and regulatory engagement for SAT-3247.
Satellos Bioscience Press release: Study update
Satellos Bioscience issued a press release on July 8, 2026, disclosing material business information to investors.
Satellos Bioscience Slides: Study update
Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on July 8, 2026.
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat ...
Satellos Bioscience Slides: Corporate presentation
Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Satellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up
(RTTNews) - Satellos Bioscience Inc. (MSLE), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SAT-3247 for the treatme...
Satellos Bioscience's Duchenne Drug SAT-3247 Wins FDA Fast Track Designation
(RTTNews) - Monday, Satellos Bioscience Inc. (MSLE) announced that the U.S. Food and Drug Administration has granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy...
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat ...
Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS?
(RTTNews) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which has revised i...
Satellos to Present Clinical Program Updates at ICNMD 2026
TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat ...
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines ...
Satellos Bioscience Transcript: Jefferies Global Healthcare Conference 2026
A novel small molecule therapy targeting muscle regeneration in DMD is advancing through two phase II trials, showing promising preclinical and clinical results, including sustained strength gains and a favorable safety profile. Full enrollment and top-line data are expected by year-end, with regulatory and financial milestones on track.
Satellos Bioscience Annual report
Satellos Bioscience has published an annual report on June 3, 2026.
Satellos to Participate in Upcoming Investor Conferences
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines t...
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines t...
Satellos Bioscience Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
A novel oral therapy for Duchenne muscular dystrophy is advancing through phase II trials, showing rapid, durable improvements in muscle strength and favorable safety. Data from pediatric and adult studies are expected in 2026, with accelerated approval targeted for 2027.
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medic...
MSLE: Analyst Sets $11 Price Target for Satellos Bioscience
MSLE: Analyst Sets $11 Price Target for Satellos Bioscience
MSLE: HC Wainwright & Co. Raises Price Target for Satellos Bioscience | MSLE Stock News
MSLE: HC Wainwright & Co. Raises Price Target for Satellos Bioscience | MSLE Stock News
Satellos Bioscience: 2025 Financial Performance
Company Overview Satellos Bioscience Inc. (NASDAQ: MSLE) is a clinical-stage biotechnology company focused on developing SAT-3247 to treat degenerative muscle... The post Satellos Bioscience: 2025 Fin...
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker "MSLE" on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a place...
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medic...
Satellos Bioscience Inc. Common Stock trading resumes
10:09 EDT Satellos (MSLE) Bioscience Inc. Common Stock trading resumes